Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | raf serine:threonine protein kinase | 0.0212 | 1 | 1 |
Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | 0.012 | 0.5298 | 0.5326 |
Echinococcus multilocularis | geminin | 0.0205 | 0.9601 | 0.9601 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.9601 | 0.9601 |
Brugia malayi | Raf kinase | 0.0205 | 0.9621 | 1 |
Echinococcus granulosus | geminin | 0.0205 | 0.9601 | 0.9601 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0067 | 0.2581 | 0.2682 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.9601 | 0.9601 |
Echinococcus granulosus | tar DNA binding protein | 0.0067 | 0.2581 | 0.2581 |
Loa Loa (eye worm) | raf kinase | 0.0211 | 0.9947 | 1 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0067 | 0.2581 | 0.2594 |
Loa Loa (eye worm) | RNA binding protein | 0.0067 | 0.2581 | 0.2594 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.2581 | 0.2581 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.2581 | 0.2581 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0017 | 0 | 0.5 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0067 | 0.2581 | 0.2682 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0212 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.2581 | 0.2581 |
Echinococcus multilocularis | tar DNA binding protein | 0.0067 | 0.2581 | 0.2581 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0017 | 0 | 0.5 |
Brugia malayi | RNA binding protein | 0.0067 | 0.2581 | 0.2682 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.2581 | 0.2581 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.2581 | 0.2581 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0017 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0017 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0067 | 0.2581 | 0.2594 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0017 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0017 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.